uMotif, a London-based eClinical startup, has raised $25. 5 million in new expansion capital from Athyrium Capital Management, the parties told Axios exclusively.
Why it matters: Features and digital generation are catalyzing on-site clinical trials and decentralized trials, but exam design is complex and traditionally challenging for the patients involved.
Details: Rothschild Athyrium on the transaction.
How it works: uMotif’s cloud-native software platform captures eCOA (electronic assessment of clinical outcomes) and ePRO (electronic patient-reported results) data, such as electronic consent data, symptoms, and wearable devices.
Between the lines: Historically, clinical trials required patients to travel to physical examination sites, but COVID has highlighted the price of decentralized trials and their ability to access patients.
Flashback: The investment follows a £5 million ($6. 3 million) Series A in 2020 led through AlbionVC and DNV, and an upcoming reorganisation in suite c.
Current situation: The players in eCOA and ePRO are Signant Health and Clario of Genstar Capital, supported by Astorg, Nordic Capital and Novo Holdings.
Yes, and: Medable, because itsArray reached a valuation of $2100 million in October from a $304 million capital injection co-led through Blackstone Growth and Tiger Global.
And then: Rosenberg envisions a long term for uMotif which is more than an eCOA and ePRO platform in addition: “I call it a 360-degree commitment. The concept is to trap [patients] in any phase and push them into the next phase of disease management.